Trials / Completed
CompletedNCT00790049
A Safety Study of ARRY-371797 in Healthy Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single Day And Multiple Day Ascending Dose Study To Evaluate The Safety And Pharmacokinetics Of Orally Administered ARRY-371797 In Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1 study, involving both 1-day and 8-day dosing periods, designed to test the safety of investigational study drug ARRY-371797 in healthy subjects. Approximately 48 healthy subjects from the US will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-371797, p38 inhibitor; oral | single dose and multiple dose, escalating |
| DRUG | Placebo; oral | matching placebo |
Timeline
- Start date
- 2008-10-31
- Primary completion
- 2009-01-21
- Completion
- 2009-01-21
- First posted
- 2008-11-13
- Last updated
- 2022-05-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00790049. Inclusion in this directory is not an endorsement.